Can a diabetes drug help hearts recover after valve surgery?

NCT ID NCT06171802

Completed Disease control Sponsor: Rigshospitalet, Denmark Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether empagliflozin (Jardiance), a diabetes drug, can help the heart recover after aortic valve replacement. 206 patients took either the drug or a placebo for six months. The goal was to see if the drug reduces heart muscle thickness and improves symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: empagliflozin (Jardiance)
What this could lead to: If it works, this could point toward a way to improve heart healing after valve replacement, potentially reducing the risk of heart failure.
What could go wrong: This is a small, early-phase 4 trial with only 206 patients. The results may not be strong enough to change practice, and empagliflozin may not provide added benefit over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AORTIC VALVE STENOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aortic valve stenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AORTIC VALVE STENOSIS

Contacts and locations

Locations

University Hospital of Copenhagen, Rigshospitalet

Copenhagen, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.